Nateglinide

209 interactions 492 cited references

Also sold as: Starlix®

About Nateglinide

Nateglinide is used alone or in combination with other medications to treat type 2 diabetes (condition in which the body does not use insulin normally and therefore cannot control the amount of sugar in the blood) in people whose diabetes cannot be controlled by diet and exercise alone. Nateglinide belongs to a class o… Read the full Nateglinide drug information page →

Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Aug 10, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Ensitrelvir Abiraterone Acetate Insulin Glulisine (Rdna Origin) Injection Chloroquine Ofloxacin Otic Letermovir Injection

1 Contraindicated 95 Major 112 Moderate 1 Minor

All (209) Contraindicated (1) Major (95) Moderate (112) Minor (1)

Major

Nateglinide Eltrombopag Alvaiz Increased OATP1B1 substrates exposure and an increased risk of OATP1B1 substrates-related adverse reactions Details Nateglinide Enoxacin Changes in blood glucose and increased risk of hypoglycemia or hyperglycemia Details Nateglinide Erythromycin Erythrocin Stearate Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse effects Details Nateglinide Fedratinib Inrebic Increased CYP3A4 substrate exposure Details Nateglinide Fexinidazole An increased CYP3A4 substrate exposure Details Nateglinide Fosnetupitant Increased exposure of CYP3A4 substrate Details Nateglinide Furosemide Disal An increased risk of hyperglycemia and an increased insulin requirement Details Nateglinide Gatifloxacin Zymaxid Changes in blood glucose and increased risk of hypoglycemia or hyperglycemia Details Nateglinide Grepafloxacin Changes in blood glucose and increased risk of hypoglycemia or hyperglycemia Details Nateglinide Hydrochlorothiazide Inzirqo An increased risk of hyperglycemia and an increased insulin requirement Details Nateglinide Hydroflumethiazide An increased risk of hyperglycemia and an increased insulin requirement Details Nateglinide Indapamide An increased risk of hyperglycemia and an increased insulin requirement Details Nateglinide Insulin Afrezza An increased risk of hypoglycemia Details Nateglinide Insulin Aspart, Recombinant Fiasp An increased risk of hypoglycemia Details Nateglinide Insulin Bovine An increased risk of hypoglycemia Details Nateglinide Insulin Degludec Tresiba An increased risk of hypoglycemia Details Nateglinide Insulin Detemir Levemir An increased risk of hypoglycemia Details Nateglinide Insulin Glargine, Recombinant Basaglar An increased risk of hypoglycemia Details Nateglinide Insulin Glulisine Apidra An increased risk of hypoglycemia Details Nateglinide Insulin Icodec-Abae Awiqli An increased risk of hypoglycemia Details Nateglinide Insulin Lispro, Recombinant Admelog An increased risk of hypoglycemia Details Nateglinide Itraconazole Sporanox Increased CYP3A4 substrate exposure and an increased risk of CYP3A4 substrate-related adverse effects Details Nateglinide Ketoconazole Extina Increased nateglinide exposure Details Nateglinide Lanreotide Acetate An increased risk of hypoglycemia and impaired glucose regulation Details Nateglinide Letermovir Prevymis Increased CYP3A substrate exposure Details Nateglinide Lomefloxacin Changes in blood glucose and increased risk of hypoglycemia or hyperglycemia Details Nateglinide Metolazone An increased risk of hyperglycemia and an increased insulin requirement Details Nateglinide Mifepristone Korlym Increased CYP3A4 substrate exposure Details Nateglinide Netupitant Increased exposure of CYP3A4 substrate Details Nateglinide Norfloxacin Changes in blood glucose and increased risk of hypoglycemia or hyperglycemia Details Nateglinide Octreotide Acetate An increased risk of hypoglycemia and impaired glucose regulation Details Nateglinide Ofloxacin Floxin® Changes in blood glucose and increased risk of hypoglycemia or hyperglycemia Details Nateglinide Omaveloxolone Skyclarys Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Nateglinide Orforglipron Foundayo An increased risk of hypoglycemia Details Nateglinide Pasireotide Diaspartate An increased risk of hypoglycemia and impaired glucose regulation Details Nateglinide Phenobarbital Fidoquel Reduced nateglinide exposure and reduced efficacy of nateglinide Details Nateglinide Polythiazide An increased risk of hyperglycemia and an increased insulin requirement Details Nateglinide Pramlintide Symlin An increased risk of hypoglycemia Details Nateglinide Primidone Mysoline Reduced nateglinide exposure and reduced efficacy of nateglinide Details Nateglinide Relacorilant Lifyorli Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse reactions Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist

Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.